""The subject database remains blinded with the current emphasis on confirmation of all data entered at study sites, as well as completion of source data verification and the necessary checks and reviews by the data management vendor in preparation of database lock.
Following database lock and transfer to the biostatistics vendor, analysis of the unblinded data from the clinical trial will begin to assess Brilacidin’s performance, against placebo, across primary, secondary, and other endpoints. Topline results are anticipated to be available one week after database lock, with full analysis to follow."
In my mind, the most difficult part of the "decision makers", is culling out all the incoming info and comparing to other released data. This is a dynamic situation, for many.
To date, ipix pronouncements come from the ceo w/o strong/any verbal backup to back-up his forward looking statements.
We all shall see.
Go ipix!